Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Achaogen
About
Achaogen, a biopharmaceutical company, discovers and develops broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $26M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2004
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 22, 2013 | Series D | $18.90M | 2 | — | — | Detail |
| Apr 7, 2010 | Series C | $56M | 1 | — | — | Detail |
| Oct 10, 2006 | Series B | $26M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series D |
Versant Ventures
|
— | Series D |
